Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a "Real World" registry
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
25917561
DOI
10.1016/j.thromres.2015.04.014
PII: S0049-3848(15)00169-3
Knihovny.cz E-zdroje
- Klíčová slova
- High residual platelet reactivity, P2Y(12) receptor antagonist, Platelet count, Platelet volume, Predictors, Selection,
- MeSH
- adenosin analogy a deriváty terapeutické užití MeSH
- akutní koronární syndrom farmakoterapie MeSH
- antagonisté purinergních receptorů P2Y chemie MeSH
- individualizovaná medicína MeSH
- klinické zkoušky jako téma MeSH
- klopidogrel MeSH
- koronární angiografie metody MeSH
- koronární angioplastika MeSH
- lidé středního věku MeSH
- lidé MeSH
- počet trombocytů MeSH
- prasugrel hydrochlorid terapeutické užití MeSH
- příjem pacientů MeSH
- prospektivní studie MeSH
- purinergní receptory P2Y12 chemie MeSH
- racionální návrh léčiv MeSH
- registrace MeSH
- senioři MeSH
- ticagrelor MeSH
- tiklopidin analogy a deriváty terapeutické užití MeSH
- trombocyty účinky léků MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- adenosin MeSH
- antagonisté purinergních receptorů P2Y MeSH
- klopidogrel MeSH
- P2RY12 protein, human MeSH Prohlížeč
- prasugrel hydrochlorid MeSH
- purinergní receptory P2Y12 MeSH
- ticagrelor MeSH
- tiklopidin MeSH
OBJECTIVE: The present study aimed to compare characteristics related to selection of a P2Y₁₂ antagonist, investigate initiation of therapy with new-generation drugs, and identify predictors of high on-treatment platelet reactivity (HTPR) in patients with acute coronary syndrome treated with stent percutaneous coronary intervention (PCI). METHODS AND RESULTS: Data from 589 patients in the LAPCOR (Laboratory AntiPlatelet efficacy and Clinical Outcome Registry; ClinicalTrials.gov Identifier: NCT02264912) registry was analyzed. P2Y₁₂ receptor antagonist efficacy was measured by VASP phosphorylation 24 ± 4 hours after a loading dose of clopidogrel (600 mg, N=407), prasugrel (60 mg, N=106), or ticagrelor (180 mg, N=76) and expressed by platelet reactivity index (PRI). HTPR was defined as PRI ≥50%. Patients treated with prasugrel were significantly younger and had significantly higher hemoglobin levels than those who received clopidogrel or ticagrelor, while chronic kidney disease was significantly more prevalent in the ticagrelor group. Almost all invasively managed patients given new-generation drugs received a loading dose after coronary angiography. Mean residual PRI and HTPR were significantly higher after clopidogrel (44.2 ± 23.1% and 42.2%, respectively) vs. prasugrel (17.7 ± 18.0% and 9.4%, respectively) or ticagrelor (18.8 ± 17.0% and 7.9%, respectively; all p<0.001). Among multiple variables tested, HTPR in patients treated with the new agents significantly related only to platelet count (p=0.014) and mean platelet volume (p=0.03). CONCLUSION: Safety is the most important aspect under consideration in choosing new agents for an individual patient. Other than platelet count and mean platelet volume, factors known as predictors of higher platelet reactivity, did not influence the efficacy of new-generation P2Y₁₂ receptor antagonists.
Citace poskytuje Crossref.org
ClinicalTrials.gov
NCT02264912
